License international

Sosei Heptares Announces Antitrust Clearance of Licensing Agreement with Neurocrine Biosciences

TOKYO, Japan and CAMBRIDGE, UK, December 23, 2021 (GLOBE NEWSWIRE) – Sosei Group Corporation (“Sosei Heptares”; TSE: 4565) today announces that under the Collaboration and License Agreement ( “License agreement”) with Neurocrine Biosciences, Inc. (“Neurocrine Biosciences”) announced on November 22, 2021, the waiting period applicable under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR Act”) expired on December 22, 2021. As such, the license The agreement entered into force on December 22, 2021. After the applicable waiting period under the HSR law has elapsed, under the terms of the license agreement , Neurocrine Biosciences has agreed to make an upfront payment of US $ 100 million to Sosei Heptares, the amount to be recognized as revenue for the fourth quarter of the fiscal year ended December 31, 2021.

About Sosei Heptares
We are a global biopharmaceutical group focused on the discovery and early development of new drugs derived from our proprietary StaR® technology targeted by GPCR and the capabilities of our structure-based drug design platform. We are developing a broad and in-depth pipeline of new drugs in multiple therapeutic areas including neurology, immunology, gastroenterology and inflammatory diseases.

We have established partnerships with some of the world’s largest pharmaceutical companies and several emerging technology companies including AbbVie, AstraZeneca, Biohaven, Genentech (Roche), GSK, Neurocrine Biosciences, Novartis, Pfizer and Takeda. Sosei Heptares is headquartered in Tokyo, Japan, with corporate and R&D facilities in Cambridge, UK.

“Sosei Heptares” is the corporate mark and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are registered trademarks of Sosei group companies.

For more information, please visit https://soseiheptares.com/
LinkedIn: @soseiheptaresco | Twitter: @soseiheptaresco | Youtube: @soseiheptaresco

Surveys:

Sosei Heptares – Press and investor relations
Hironoshin Nomura, SVP Investor Relations and Corporate Strategy
+81 (0) 3 6679 2178 | [email protected]

Shinichiro Nishishita, Vice President of Investor Relations, Head of Regulatory Disclosure
+81 (0) 3 5210 3399 | [email protected]

Citigate Dewe Rogerson (for Japanese media)
Yas Fukuda
+81 (0) 3 4360 9234 | [email protected]

MEDiSTRAVA Consulting (for international media)
Mark Swallow, David Dible, Eleanor Perkin
+44 (0) 20 7638 9571 | [email protected]

Forward-looking statements
This press release contains forward-looking statements, including statements regarding the discovery, development and commercialization of products. Various risks may cause Sosei Group Corporation’s actual results to differ materially from those expressed or implied by forward-looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence on strategic alliance partners to develop and market products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to carry out research and development activities and to expand commercialization activities; and product initiatives by competitors. Because of these factors, potential investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.


Source link